

CIPHERPOINT

Zusammenfassung der ASX-Meldungen vom 30 Januar 2020

30 Januar 2020

Cipherpoint: Quartals- & 9-Monatszahlen

Cipherpoint hat kürzlich die Zahlen zum abgelaufenen Quartal Okt-Dez sowie der vergangenen neun Monate veröffentlicht.

Finanzielle Highlights

Die Cash-Position konnte im abgelaufenen Quartal um ca. 0,5 Mio. AU\$ erhöht werden auf nun 1,8 Mio. AU\$. Ursächlich für diese Erhöhung sind erhaltene Zahlungen, die das Unternehmen für den Verkauf des SafeShare-Geschäfts erhalten hat. Diese beliefen sich im abgelaufenen Quartal auf 1,1 Mio. AU\$. Der Cash Flow aus operativer Tätigkeit hingegen ist mit minus 0,15 Mio. AU\$ leicht negativ. Hier sind es erhaltene staatliche Subventionen in Höhe von 0,8 Mio. AU\$, die einen deutlich negativeren operativen Cash Flow abfangen konnte. Denn die Umsätze im abgelaufenen Quartal betragen „nur“ 44.000 AU\$. Ursache für die niedrigen Umsätze liegen u.a. im Verkauf des SafeShare-Geschäfts, die in der Vergangenheit ein deutlicher Umsatzbringer war. Die wichtigsten Cash-Flow-Kennzahlen des abgelaufenen Quartals im Überblick:

1. Cash Flow aus operativer Tätigkeit:

Umsätze	44T AU\$
Kosten	-1.086T AU\$
Staatliche Subventionen	810T AU\$
Operatives NetCash	-148T AU\$

Jahres-Chart Cipherpoint



Quelle: Comdirect

Börse:	ASX
Code:	ASX: CVT
Anzahl Aktien	782,9 Mio.
GICS ind. group:	Software & Services

Kennzahlen Cipherpoint

Halbjahr April– Dezember 2019

Umsätze: ²	AU\$ 1,2 Mio.
Kosten:	AU\$ -2,8 Mio.
NetCash Operative Act	AU\$ -2,7 Mio.
NetCash Investing Act.	AU\$ 2,6 Mio.
NetCash Financing Act	AU\$ 0,4 Mio.
Cash&Equivalents 31.12.	AU\$ 1,8 Mio.

All information and advice is confidential and for the private information of the person to whom it is provided and is provided without any responsibility or liability on any account whatsoever on the part of this firm or any member or employee thereof.

This paper is a marketing communication only and does not constitute nor does it contain an offer or invitation to buy or subscribe for securities in any of the companies listed, nor is it an inducement to make an offer or invitation with respect to any of the securities within. This information is intended solely for professional investors in the capital markets. The paper is not meant for private investors or other groups and is not to be forwarded to them. Please take note of this disclaimer.

CIPHERPOINT

Zusammenfassung der ASX-Meldungen vom 30. Januar 2020

30 Januar 2020

2. Cash Flow aus Investitionstätigkeiten

Zahlungen an dataglobal für Lizenz Datenklassifizierung	-485T AU\$
Erhaltene anteilige Zahlungen für den Verkauf von SafeShare	1.136T AU\$
Cash Flow aus Investitionstätigkeiten	630T AU\$

3. Cash Flow aus Finanzierungstätigkeiten

Ausgabe von Wandelanleihen	500T AU\$
Cash Flow aus Finanzierungstätigkeiten	429T AU\$

Cash & Cash Equivalents, 31.12.2019	1.755T AU\$
-------------------------------------	-------------

Operative Highlights

Cipherpoint (vormals Covata Limited) hat eine Tochtergesellschaft in Deutschland, Baden-Württemberg eröffnet. Die Aufgabe der Cipherpoint GmbH wird es sein, das Geschäft vor allem im deutschsprachigen Europa (Deutschland, Schweiz, Österreich) voranzutreiben. Darüberhinaus gab es eine Erweiterung in der Unternehmensführung: Grahjma Mirabito, der frühere CEO von CoreLogic RP Data Ltd. ist in die Unternehmensführung berufen worden.

Aussicht für das Quartal Jan - März sowie für das Jahr 2020

Nachdem das Cocoon Group Business nun komplett verkauft wurde, erwartet Cipherpoint einen ScaleUp-Prozess sowie Erneuerungen im Business mit bestehenden Eclipse Kunden. Darüber hinaus - so das Unternehmen - erwartet Cipherpoint weitere Kunden und Partner in Europa und im Asian Pacific-Raum für seine Produkte cp.Protect, cp.Discover sowie cp.OEM

All information and advice is confidential and for the private information of the person to whom it is provided and is provided without any responsibility or liability on any account whatsoever on the part of this firm or any member or employee thereof.

This paper is a marketing communication only and does not constitute nor does it contain an offer or invitation to buy or subscribe for securities in any of the companies listed, nor is it an inducement to make an offer or invitation with respect to any of the securities within. This information is intended solely for professional investors in the capital markets. The paper is not meant for private investors or other groups and is not to be forwarded to them. Please take note of this disclaimer.

DR REUTER INVESTOR RELATIONS

SPEZIALIST IN INVESTOR RELATIONS WORK ON THE EUROPEAN CAPITAL MARKETS
 FRIEDRICH EBERT ANLAGE 35-37
 TOWER 185
 60327 FRANKFURT
 DR. EVA REUTER, TEL. +49 251 7 32 862
 E.REUTER@DR-REUTER.EU

Disclaimer

The information and opinions given in this note have been drawn up by Dr. Reuter Investor Relations. This note has been exclusively published for informative purposes and represents neither a request, quotation nor a recommendation for buying or selling investment instruments or for effecting other transactions. Moreover, neither this publication nor its information forms the basis for a contract or a commitment of any kind. Any investment in shares, loans and options is faced with risks.

The information and data come from sources which Dr. Reuter Investor Relations considers to be reliable. However, Dr Reuter Investor Relations do not assume any responsibility for the correctness and completeness of the information and data. Neither the writer nor Dr. Reuter Investor Relations are liable for losses or damage of any kind in connection with the content of this information brochure. By accepting this document you agree to the provisions previously noted as being mandatory for the recipient. Share prices can vary and corporate value can rise/fall. Any reference to the previous trend in value is not necessarily an indicator of developments to come. Rates of exchange can adversely affect the value trend, price and earnings of any company mentioned here. Reference is also made here to possible political, economic, credit, foreign exchange and market risks. Investment in any of the companies mentioned should only be done after studying the most recent brochure and other company/market information available and /or obtaining appropriate professional advice. Corporate brochures can be obtained from the companies in question. The reader should evaluate any investment in any of the companies mentioned there in the light of their own professional advice, circumstances and investment goals. The recommendation of Dr. Reuter Investor Relations - in the event of any investments - is to consult a qualified professional consultant as to the specific financial risks and the statutory, official, credit, fiscal and settlement-induced consequences. It is quite possible that the issuers of the securities mentioned here have acted at variance to the facts of the case specified herein without Dr. Reuter Investor Relations being

aware of this development.

In drawing up this paper, the following conflicts of interest cannot be categorically ruled out:

1. The companies specified may be Dr. Reuter Investor Relations customers and this publication is undertaken as part of the investor relations service package.
2. This publication was presented to the companies specified before publication and may have been changed at the company's request.
3. Dr Reuter Investor Relations and/or an affiliated company or the writer may have long or short positions in the companies specified.

This paper includes the following possible conflicts of interest: Cipherpoint is a customer of Dr. Reuter Investor Relations.

Some of the following detailed statements are based on translations of corporate news and company documentation. No liability is assumed for the translations. Please refer to the original English notifications and original documents.

Disclaimer United States:

1. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
2. This news release does not constitute an offer to sell or other solicitation of an offer to buy any ordinary shares within the United States. The ordinary shares have not been offered and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws. Accordingly, the ordinary shares may not be offered or sold in the United States or to U:S Persons (as such terms are defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is granted.
3. Information and investment comments are independently and thoroughly researched and believed correct. No guaranty of absolute accuracy can be given however. Investment decisions are fully made for own risk.